Publications and presentations
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N.N Engl J Med. 2022 Apr 14;386(15):1421-1431
Registries in immune thrombocytopenia (ITP) in Europe: the European Research Consortium on ITP (ERCI) network. Moulis G, Cooper N, Ghanima W, González-López T, Kühne T, Lozano ML, Michel M, Provan D, Zaja F, Aladjidi N, Christiansen CF, Frederiksen H, Grainger J, McDonald V, Robinson S, Schifferli A, Rodeghiero F. Br J Haematol. 2022 Mar 18.
Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in the United Kingdom and Ireland (TRAPeze UK & IE study). McDonald, Vickie; Newland, Adrian; Morgan, Mervyn; Wilson, Koo; Nazir, Jameel; Maguire, Peter; Geldman, Emma; Wynne, Tammy. Hematology . 2021 Dec;26(1):799-808
Evans syndrome in adults: an observational multicenter study. Fattizzo B, Michel M, Giannotta JA, Hansen DL, Arguello M, Sutto E, Bianchetti N, Patriarca A, Cantoni S, Mingot-Castellano ME, McDonald V, Capecchi M, Zaninoni A, Consonni D, Vos JM, Vianelli N, Chen F, Glenthøj A, Frederiksen H, González-López TJ, Barcellini W. Blood Adv. 2021 Dec 28;5(24):5468-5478
How Effective Are the Immunosuppressive Therapies Rituximab and Mycophenolate Mofetil in Immune Thrombocytopenia? Real World Evidence from the UK ITP Registry. Vickie McDonald, Gerorge Loughlin, Andrew Laws, Duncan Stacey, Jeffrey Spears, Atiqa Miah, Haroon Miah, Quentin Hill, Nichola Cooper, Michael Makris, Charlotte Bradbury, Adrian C. Newland
FcRn antagonists in ITP. Newland, Adrian C; McDonald, Vickie; Annals Blood; Vol 6; March 2021
Efficacy and Safety of Intravenous Efgartigimod 10 Mg/Kg in Adult Patients with Primary Immune Thrombocytopenia: Advance, a Phase 3 Clinical Trial in Progress. Adrian C. Newland, Howard A. Liebman, MD, Vickie McDonald, MD, Marc Michel, Yoshitaka Miyakawa, Wim Parys, MD, Hans De Haard, Peter Ulrichts, Marie Godar, Kristof De Beuf, Jaume Ayguasanosa, Catherine M Broome, David J. Kuter, MD. Blood (Nov 2020) 136 (Supplement 1): 6–7.
Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia. Adrian Newland and Vickie McDonald. Immunotherapy. 10.2217/imt-2020-0215. Oct 2020.
Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Provan, Drew; Arnold, Donald M; Bussel, James B; Chong, Beng H; Cooper, Nichola; Gernsheimer, Terry; Ghanima, Waleed; Godeau, Bertrand; González-López, Tomás José; Grainger, John; , Ming Hou, Caroline Kruse, Vickie McDonald, Marc Michel, Adrian C Newland, Sue Pavord, Francesco Rodeghiero, Marie Scully, Yoshiaki Tomiyama, Raymond S Wong, Francesco Zaja, David J Kuter. Blood Adv. 2019 Nov 26;3(22):3780-3817
Fostamatinib for persistent/chronic adult immune thrombocytopenia. Newland A, Lee EJ, McDonald V, Bussel JB. Immunotherapy. 2018 Jan;10(1):9-25
Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia. Cines DB, Wasser J, Rodeghiero F, Chong BH, Steurer M, Provan D, Lyons R, Garcia-Chavez J, Carpenter N, Wang X, Eisen M. Haematologica. 2017 Aug;102(8):1342-1351
Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Quentin Hill, Robert Stamps, Edwin Massey, John Grainger, Drew Provan and Anita Hill, Brit J Haemat, 2017, 177, 208-220
Comparison of the effects of the TPO receptor agonist, Romiplostim, in patients with ITP < 1yr versus > 1yr. DJ Kuter, AC Newland, BH Chong, F Rodegheiro, MT Romero, I Pabinger, Y Chen, B Metha, M Eisen. ASH 2017; BLOOD 2017, 130, 1055
Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. Doobaree IU, Nandigam R, Bennett D, Newland A, Provan D. Eur J Haematol. 2016 Oct;97(4):321-30
Current Management of Primary Immune Thrombocytopenia. Drew Provan and Adrian C. Newland. Adv Ther. 2015; 32(10): 875–887. Published online 2015 Oct 26. doi: 10.1007/s12325-015-0251-z
Jul 2022 - Paradigm shift in ITP treatment patterns in the era of the COVID-19 pandemic opportunity to study real world outcomes from established platform: Update from UK Adult ITP registry. Haroon Miah et al
Jul 2022 - Thrombopoietin receptor agonists (TPO-RAs) in older patients with primary immune thrombocytopenia (ITP): effective and safe? Real World Data from the UK adult ITP registry. Priyanka Raheja, et al
Apr 2022 - Real world evidence from the UK ITP Registry on the effectiveness of the immunosuppressive therapies rituximab and mycophenolate mofetil in immune thrombocytopenia. McDonald V et al
Jan 2022 - ASH Poster - How Effective Are the Immunosuppressive Therapies Rituximab and Mycophenolate Mofetil in Immune Thrombocytopenia? Real World Evidence from the UK ITP Registry.
July 2021 - ISTH Virtual Poster - Therapeutic landscape in primary immune thrombocytopenia over the last three decades in the United Kingdom.
July 2020 - Virtual presentation with Haemostasis Connect - Current perspectives on the treatment of primary chronic ITP in adults: CME-accredited, independent, virtual symposium
Poster presentation, 2019, European Haematology Association (EHA) - Splenectomy in immune thrombocytopenia: do changing treatment patterns for ITP effect outcomes? Data from the UK ITP registry. Todd S et al
Poster presentation, 2018, EHA - Epidemiology and Management of Primary Immune Thrombocytopenia: Real world data from the UK ITP Registry. Zaidi A et al
Oral presentation, 2018, British Society for Haematology (BSH) - Comparison of standard- and low-dose rituximab in Primary Immune Thrombocytopenia (ITP): data from the UK ITP registry. C Gracie et al